|
How many volunteers were present at the Congress? : |
1400 |
|
Delegates from which countries presented in the congress? : |
All over the world such as USA - Canada - Brazil - China - Germany. |
|
Were the delegates of any other organizations present in the congress? : |
Yes |
|
If yes, please write the names of the organizations in the box : |
Iranian Neurosurgical Society, Iranian Orthopedic society |
|
What were the responses to your talking points? Were specific questions or concerns raised? : |
The response to our talking points were excellent. There were specific questions about the methodology and results. The detail of methods and results were: We included randomized controlled trials (RCTs) and prospective non-randomized controlled clinical trials assessing VP or KP compared with each other, usual care or other treatments for the treatment of pain following MSL without cord compression. We searched MEDLINE, EMBASE, PubMed and CENTRAL.
Results: The literature search revealed 387 citations. Of these, nine trials met all eligibility criteria and included in the qualitative analysis. In total, there were 622 patients enrolled in the trials and of these 432 were in surgical treatment group (92 received KP, 97 received VP, 134 received VP and chemotherapy, 68 received VP and radiotherapy and 41 received Kiva implant) and 190 were in non-surgical treatment group (83 received chemotherapy, 46 received radiotherapy and 61 received other treatment). Using the grade approach, pain (low quality evidence) and functional scores (very low quality evidence) improved more with VP plus chemotherapy than with chemotherapy alone (Pain: mean difference (MD): -3.01; 95%CI: -3.21 to -2.80; functional score: MD: 15.46; 95%CI: 13.58 to 17.34). KP seemed to lead to significantly greater improvement in Pain, disability and health-related quality of life (HRQoL) compared to NSM. VP plus Iodine-125 seemed to lead to significantly greater improvement in pain and disability in comparison with VP alone. VP plus radiochemotherapy have a better pain relief and HRQoL post-operatively in comparison with routine radiochemotherapy. |
|
If you met staff members, please list their full names & positions. : |
Jeff Wang - The past president of International AOSpine; Raja - AOSpine International research; MG Fehlings - AOSpine forum Spinal cord; Dan Riew -AOSpine International president; Jens Chapman - Chief Editor of Global Spine Journal |
|
Please inform us if there are any follow up actions we need to talk with the members of the congress : |
In addition to my presentation, our congress had other fruitful results. Based on the international communication in the congress, and my responsibility as a director of national spinal cord injury registry of Iran, I talked to our spine organization to see if they support us for development of spine fracture registry in the Middle East. Therefore, we started to write a proposal to the spine organization and extend our communication with all known experts.
We would appreciate it if our University can expand the responsibility to the Middle East and be the first in the region in the field of spinal cord injury registry in the region.
The spine is the most common site of bone metastases. Vertebroplasty (VP) and Kyphoplasty (KP) have been proposed as potential minimally invasive therapeutic options for metastatic spinal lesion (MSL) pain. However, the efficacy of VP and KP on MSL pain is currently unclear.
The Objective of the present review was to assess the effects of VP and KP on pain, disability and quality of life following MSL.
We included randomized controlled trials (RCTs) and prospective non-randomized controlled clinical trials assessing VP or KP compared with each other, usual care or other treatments for the treatment of pain following MSL without cord compression. We searched MEDLINE, EMBASE, PubMed and CENTRAL.
The literature search revealed 387 citations. Of these, nine trials met all eligibility criteria and included in the qualitative analysis. In total, there were 622 patients enrolled in the trials and of these 432 were in surgical treatment group (92 received KP, 97 received VP, 134 received VP and chemotherapy, 68 received VP and radiotherapy and 41 received Kiva implant) and 190 were in non-surgical treatment group (83 received chemotherapy, 46 received radiotherapy and 61 received other treatment). Using the grade approach, pain (low quality evidence) and functional scores (very low quality evidence) improved more with VP plus chemotherapy than with chemotherapy alone (Pain: mean difference (MD): -3.01; 95%CI: -3.21 to -2.80; functional score: MD: 15.46; 95%CI: 13.58 to 17.34). KP seemed to lead to significantly greater improvement in Pain, disability and health-related quality of life (HRQoL) compared to NSM. VP plus Iodine-125 seemed to lead to significantly greater improvement in pain and disability in comparison with VP alone. VP plus radiochemotherapy have a better pain relief and HRQoL post-operatively in comparison with routine radiochemotherapy.
Based on the analysis of currently published trial data, it is unclear whether VP for MSL provides benefits over KP.
|
|
Your experiences about the travel processes(Providing ticket, accommodation,...) : |
Our experience about the travel processes including ticket, accommodation and meal was excellent and every thing was smooth. |
|
Please give a briefing of your own observations and outcomes of the congress: : |
Our own observations and outcomes of the congress were excellent. It was fruitful congress and we discuss many scientific issues including our National registry and their external evaluations including imaging of AOSpine fracture classifications and NSCIR.
Title: Vertebroplasty and Kyphoplasty for metastatic spinal lesions: A systematic review
Author
Vafa Rahimi-Movaghar, MD
Professor of Neurosurgery
Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences
Tehran, Iran
Abstract
Background: The spine is the most common site of bone metastases. Vertebroplasty (VP) and Kyphoplasty (KP) have been proposed as potential minimally invasive therapeutic options for metastatic spinal lesion (MSL) pain. However, the efficacy of VP and KP on MSL pain is currently unclear.
Objective: The Objective of the present review was to assess the effects of VP and KP on pain, disability and quality of life following MSL.
Method: We included randomized controlled trials (RCTs) and prospective non-randomized controlled clinical trials assessing VP or KP compared with each other, usual care or other treatments for the treatment of pain following MSL without cord compression. We searched MEDLINE, EMBASE, PubMed and CENTRAL.
Results: The literature search revealed 387 citations. Of these, nine trials met all eligibility criteria and included in the qualitative analysis. In total, there were 622 patients enrolled in the trials and of these 432 were in surgical treatment group (92 received KP, 97 received VP, 134 received VP and chemotherapy, 68 received VP and radiotherapy and 41 received Kiva implant) and 190 were in non-surgical treatment group (83 received chemotherapy, 46 received radiotherapy and 61 received other treatment). Using the grade approach, pain (low quality evidence) and functional scores (very low quality evidence) improved more with VP plus chemotherapy than with chemotherapy alone (Pain: mean difference (MD): -3.01; 95%CI: -3.21 to -2.80; functional score: MD: 15.46; 95%CI: 13.58 to 17.34). KP seemed to lead to significantly greater improvement in Pain, disability and health-related quality of life (HRQoL) compared to NSM. VP plus Iodine-125 seemed to lead to significantly greater improvement in pain and disability in comparison with VP alone. VP plus radiochemotherapy have a better pain relief and HRQoL post-operatively in comparison with routine radiochemotherapy.
Conclusion: Based on the analysis of currently published trial data, it is unclear whether VP for MSL provides benefits over KP.
Key words: Metastatic spinal lesion, Vertebroplasty, Kyphoplasty, Systematic review, Pain, Disability, Quality of life
|